These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
423 related articles for article (PubMed ID: 36275676)
1. Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma. Yu X; Chen P; Yi W; Ruan W; Xiong X Front Immunol; 2022; 13():1029872. PubMed ID: 36275676 [TBL] [Abstract][Full Text] [Related]
2. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma. Luo Y; Liu H; Fu H; Ding GS; Teng F Front Immunol; 2022; 13():974377. PubMed ID: 36458010 [TBL] [Abstract][Full Text] [Related]
3. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma. Gao S; Zhang L; Wang H Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264 [TBL] [Abstract][Full Text] [Related]
4. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma. Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679 [TBL] [Abstract][Full Text] [Related]
5. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma. Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X Front Immunol; 2023; 14():1218661. PubMed ID: 37662906 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma. Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z Front Immunol; 2022; 13():934243. PubMed ID: 36189255 [TBL] [Abstract][Full Text] [Related]
7. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma. Tang B; Zhang X; Yang X; Wang W; Li R; Liu Y Front Immunol; 2022; 13():1013248. PubMed ID: 36466855 [TBL] [Abstract][Full Text] [Related]
8. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes. Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value and potential mechanism of cellular senescence and tumor microenvironment in hepatocellular carcinoma: Insights from bulk transcriptomics and single-cell sequencing analysis. Qu C; Wu Q; Lu J; Li F Environ Toxicol; 2024 May; 39(5):2512-2527. PubMed ID: 38189188 [TBL] [Abstract][Full Text] [Related]
10. The significance of m6A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma. Fang Q; Chen H Mol Med; 2020 Jun; 26(1):60. PubMed ID: 32552682 [TBL] [Abstract][Full Text] [Related]
11. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma. Mo Z; Liu D; Rong D; Zhang S Front Immunol; 2021; 12():611058. PubMed ID: 33679749 [No Abstract] [Full Text] [Related]
12. Identification and validation of redox-immune based prognostic signature for hepatocellular carcinoma. Tu K; Li J; Mo H; Xian Y; Xu Q; Xiao X Int J Med Sci; 2021; 18(9):2030-2041. PubMed ID: 33850474 [TBL] [Abstract][Full Text] [Related]
13. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma. Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595 [TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of a novel molecular classification based on disulfidptosis-related genes to predict prognosis and immunotherapy efficacy in hepatocellular carcinoma. Yang L; Zhang W; Yan Y Aging (Albany NY); 2023 Jul; 15(13):6135-6151. PubMed ID: 37399661 [TBL] [Abstract][Full Text] [Related]
15. Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making. Chen J; Gao G; He Y; Zhang Y; Wu H; Dai P; Zheng Q; Huang H; Weng J; Zheng Y; Huang Y Sci Rep; 2023 Dec; 13(1):22624. PubMed ID: 38114725 [TBL] [Abstract][Full Text] [Related]
16. Cuproptosis-related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features. Li S; Weng J; Xiao C; Lu J; Cao W; Song F; He Z; Zhang P; Zhu Z; Xu J Cancer Rep (Hoboken); 2023 Dec; 6(12):e1904. PubMed ID: 37885090 [TBL] [Abstract][Full Text] [Related]
17. Identification of a senescence-related transcriptional signature to uncover molecular subtypes and key genes in hepatocellular carcinoma. He X; Liu F; Gong Q PLoS One; 2024; 19(10):e0311696. PubMed ID: 39383169 [TBL] [Abstract][Full Text] [Related]
18. Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma. Zhang X; Zhuge J; Liu J; Xia Z; Wang H; Gao Q; Jiang H; Qu Y; Fan L; Ma J; Tan C; Luo W; Luo Y Front Immunol; 2023; 14():1153423. PubMed ID: 37006285 [TBL] [Abstract][Full Text] [Related]
19. Significance of tumor-infiltrating immunocytes for predicting prognosis of hepatitis B virus-related hepatocellular carcinoma. Chen QF; Li W; Wu PH; Shen LJ; Huang ZL World J Gastroenterol; 2019 Sep; 25(35):5266-5282. PubMed ID: 31558872 [TBL] [Abstract][Full Text] [Related]
20. Characterization of the Prognosis and Tumor Microenvironment of Cellular Senescence-related Genes through scRNA-seq and Bulk RNA-seq Analysis in GC. Guo G; Zhou Z; Chen S; Cheng J; Wang Y; Lan T; Ye Y Recent Pat Anticancer Drug Discov; 2024; 19(4):530-542. PubMed ID: 37807645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]